A detailed history of Virtus ETF Advisers LLC transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 8,298 shares of IMCR stock, worth $247,861. This represents 0.13% of its overall portfolio holdings.

Number of Shares
8,298
Previous 8,298 -0.0%
Holding current value
$247,861
Previous $281,000 8.19%
% of portfolio
0.13%
Previous 0.14%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$33.78 - $63.75 $78,910 - $148,920
2,336 Added 39.18%
8,298 $281,000
Q1 2024

May 15, 2024

BUY
$60.14 - $75.36 $51,600 - $64,658
858 Added 16.81%
5,962 $387,000
Q4 2023

Feb 15, 2024

SELL
$42.85 - $69.5 $6,898 - $11,189
-161 Reduced 3.06%
5,104 $348,000
Q3 2023

Nov 07, 2023

SELL
$49.5 - $66.6 $33,858 - $45,554
-684 Reduced 11.5%
5,265 $273,000
Q2 2023

Aug 14, 2023

BUY
$48.54 - $61.64 $35,045 - $44,504
722 Added 13.81%
5,949 $356,000
Q1 2023

May 15, 2023

BUY
$46.12 - $65.71 $4,427 - $6,308
96 Added 1.87%
5,227 $258,000
Q4 2022

Feb 14, 2023

SELL
$45.51 - $65.08 $159,603 - $228,235
-3,507 Reduced 40.6%
5,131 $292,000
Q3 2022

Nov 14, 2022

BUY
$37.34 - $57.44 $4,667 - $7,180
125 Added 1.47%
8,638 $405,000
Q2 2022

Aug 12, 2022

BUY
$25.46 - $37.72 $83,941 - $124,362
3,297 Added 63.21%
8,513 $318,000
Q1 2022

May 16, 2022

SELL
$18.94 - $34.29 $5,814 - $10,527
-307 Reduced 5.56%
5,216 $156,000
Q4 2021

Feb 14, 2022

BUY
$27.58 - $40.0 $4,523 - $6,560
164 Added 3.06%
5,523 $189,000
Q3 2021

Nov 15, 2021

SELL
$27.98 - $40.0 $7,694 - $11,000
-275 Reduced 4.88%
5,359 $199,000
Q2 2021

Aug 10, 2021

BUY
$32.22 - $41.5 $181,527 - $233,811
5,634 New
5,634 $220,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.31B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.